BioLargo, Inc.
BLGO
$0.2639
-$0.0002-0.08%
| Weiss Ratings | BLGO - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | BLGO - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Fair | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | BLGO - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.18 | |||
| Price History | BLGO - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 3.53% | |||
| 30-Day Total Return | 0.92% | |||
| 60-Day Total Return | 35.13% | |||
| 90-Day Total Return | 12.39% | |||
| Year to Date Total Return | 17.18% | |||
| 1-Year Total Return | -22.38% | |||
| 2-Year Total Return | 25.67% | |||
| 3-Year Total Return | 16.00% | |||
| 5-Year Total Return | 40.75% | |||
| 52-Week High % Change | -30.48% | |||
| 52-Week Low % Change | 64.45% | |||
| Price | BLGO - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $0.38 | |||
| 52-Week Low Price | $0.16 | |||
| 52-Week Low Price (Date) | Dec 18, 2024 | |||
| 52-Week High Price (Date) | Mar 20, 2024 | |||
| Valuation | BLGO - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 79.51M | |||
| Enterprise Value | 74.46M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.01 | |||
| Earnings Per Share Growth | -47.45% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 4.29 | |||
| Price/Book (Q) | 9.27 | |||
| Enterprise Value/Revenue (TTM) | 4.03 | |||
| Price | $0.26 | |||
| Enterprise Value/EBITDA (TTM) | -23.26 | |||
| Enterprise Value/EBIT | -22.39 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | BLGO - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 300.49M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | BLGO - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 888 400 2863 | |||
| Address | 14921 Chestnut Street Westminster, CA 92683 | |||
| Website | www.biolargo.com | |||
| Country | United States | |||
| Year Founded | 1991 | |||
| Profitability | BLGO - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -17.97% | |||
| Profit Margin | -11.44% | |||
| Management Effectiveness | BLGO - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -24.67% | |||
| Return on Equity | -- | |||
| Income Statement | BLGO - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 18.50M | |||
| Total Revenue (TTM) | 18.50M | |||
| Revenue Per Share | $0.06 | |||
| Gross Profit (TTM) | 8.19M | |||
| EBITDA (TTM) | -3.20M | |||
| EBIT (TTM) | -3.33M | |||
| Net Income (TTM) | -2.12M | |||
| Net Income Avl. to Common (TTM) | -2.12M | |||
| Total Revenue Growth (Q YOY) | 62.84% | |||
| Earnings Growth (Q YOY) | 29.71% | |||
| EPS Diluted (TTM) | -0.01 | |||
| EPS Diluted Growth (Q YOY) | 57.14% | |||
| Balance Sheet | BLGO - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 3.88M | |||
| Cash Per Share (Q) | $0.01 | |||
| Total Current Assets (Q) | 7.39M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 5.98M | |||
| Current Ratio (Q) | 2.311 | |||
| Book Value Per Share (Q) | $0.03 | |||
| Total Assets (Q) | 10.31M | |||
| Total Current Liabilities (Q) | 3.20M | |||
| Total Debt (Q) | 1.43M | |||
| Total Liabilities (Q) | 4.32M | |||
| Total Common Equity (Q) | 8.58M | |||
| Cash Flow | BLGO - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -1.41M | |||
| Cash from Financing (TTM) | 3.61M | |||
| Net Change in Cash (TTM) | 840.00K | |||
| Levered Free Cash Flow (TTM) | -1.21M | |||
| Cash from Operations (TTM) | -1.29M | |||
